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Introduction
The World Health Organization (WHO) defined papillary thyroid microcarcinomas (PTMC) as tumors
measuring 1.0 cm or less in diameter (1, 2). These tumors are often not detectable by clinical examination,
and commonly found incidentally either after a total thyroidectomy is performed for other indications or
during thyroid ultrasound. Incidental PTMC is defined as a postsurgical diagnosis of microcarcinoma with
benign clinical course3. PTMC is also referred to as minimal, small, tiny, or minute carcinomas (4-7).
Some authors suggest that small papillary carcinomas found at histology should be called occult papillary
“tumors” instead of carcinomas to reflect its benignity and to avoid the culture stigma associated with a
cancer diagnosis (8).
Discriminating between an incidental PTMC or invasive PTMC intraoperatively is essential. In this study,
we analyzed the clinicopathology parameters between incidental PTMC and non-incidental PTMC study
in order to test  the  hypothesis that  less aggressive  surgical treatments,  such as lobectomy or subtotal
thyroidectomy, are sufficient for incidental PTMC.
Although PTMC is considered a benign disease, it can have a variable biologic behavior. While the tumor
cannot be palpated in the thyroid clinically, palpable lymph node metastasis may be found in a subset of
patients. Nodal involvement rate is lower in PTMC compared to tumors larger than 1 cm. It has been
reported that lymph node metastases were detected in 3.1–18.2% of patients with PTMC (9, 10). Lymph
node metastasis at diagnosis is a predictive factor for loco-regional recurrence and distant metastasis for
PTMC (11). In this study, we analyzed the factors predictive of central cervical lymph node metastasis
from PTMC and tested the hypothesis that more aggressive surgical treatments such as near-total or total
thyroidectomy with central cervical lymph node dissection are adequate procedures for non-incidental
PTMC.
Materials and methods
Patients and operation
From December  1993 to  October  2008,  588  papillary  thyroid  carcinoma  patients underwent  surgical
treatment and were followed by our service at Shanghai Renji Hospital, China. Among them, 177 cases
(30.1%) were  PTMC as determined by histopathology.  All patients received primary thyroid surgical
resection and received follow-up care from service.
The 177 PTMC patients were divided into 2 groups. Fifty-four patients in group 1 were classified as
incidental PTMC,  while  123  patients  in  group  2  were  classified  as non-incidental PTMC.  Incidental
PTMC  was  defined  as  a  postsurgical  diagnosis  of  microcarcinoma  with  benign  clinical  course.
Non-incidental  PTMC was  defined  by  histopathology  before  the  operation  by  fine-needle  aspiration
biopsy or during the operation by frozen sections.
Patients in group 1 were diagnosed by palpation or neck ultrasound. No patient  was found to have a
suspicious cervical lymph node before operation. These patients received a  subtotal thyroidectomy or
lobectomy.  Subtotal thyroidectomy was  defined  as  removing more  than  50% of  the  entire  gland  on
abnormal lobe(s). Patients were treated with postoperative suppressive L-thyroxine (L-T4) therapy.
Patients in group 2 whose malignancy was confirmed by fine-needle aspiration biopsy or by frozen section
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underwent a near-total or total thyroidectomy and a central cervical lymph node dissection. When the
patient had the nodule(s) in only one lobe, he underwent a near-total thyroidectomy, when the patient had
the nodule(s) in both lobes, he underwent a total thyroidectomy. Near-total thyroidectomy was defined as
a total lobectomy in the lobe with the dominant nodule, with isthmectomy and near-total lobectomy on the
contralateral side leaving thyroid posterior capsule, adjacent parathyroid glands, and blood supply. All the
patients in group 2 received a central cervical lymph node dissection systematically. Fifty two patients in
group 2 with concurrent neck lymphadenopathy by palpation or by neck ultrasound received a unilateral
selective neck dissection, including level II-IV and VI. One patient with a suspicious cervical lymph node
bilateral  underwent  a  bilateral  selective  neck  dissection.  Patients  were  treated  with  postoperative
suppressive L-thyroxine (L-T4) therapy as done in group 1.
Statistical analysis
Categorical variables were compared using the t-Test Procedure (Table 1), the FREQ Procedure (Tables
1, 2), Fisher Exact Test (Tables 1, 2) and the Logistic Procedure (Table 3). P  values were two-sided.
Differences were considered significant for p<0.05. Statistical analyses were performed using SAS version
6.12 software.
Results
Presentation of PTMC in 2 groups
The mean age of patients in group 1 is older than that in group 2 (49.6±8.9 versus 44.4±9.5, p<0.01)).
Histological examination  showed  that  patients  in  group  1  had  a  smaller  tumor  size  than  in  group  2
(0.33±0.21 versus 0.71±0.23,  p<0.01).  No statistical difference  of sex distribution,  multifocal ratio or
prognosis were noted between group 1 and 2. Table 1 illustrated the age, gender, tumor size, multifocal
and prognosis distribution of 177 PTMC patients in different groups.
Follow-up
No  clinically  important  complications  were  found  which  defined  as  permanent  hypocalcemia  and
permanent vocal paralysis. All patients received postoperative thyroid stimulating hormone suppression
thyroxine therapy. No one received radioiodine, even for patients with known nodal metastatic thyroid
disease. Patients were followed up until June 2009, prospectively from 11 to 188 months (mean: 59.73
months) according to Société Française d’Oto-Rhino-Laryngologie et de Chirurgie de la Face et du Cou
Practice Guidelines (12). No mortality was recorded during the follow-up period. Ten-year disease-free
and overall survival rates were  99.4% and 100%, respectively.  No distant  metastasis was determined
during the follow-up period. The recurrence was defined by histopathology during the period. One patient
in group 2 who underwent a near total thyroidectomy and right sided selective neck dissection for PTMC
in the right lobe on November 1997 recurred in the left lobe 78 months after the initial operation. As we
did not find the cervical lymph node metastasis, this patient underwent total thyoidectomy at May 2004.
She was followed until now, no recurrence or distant metastasis was recorded.
Factors predictive of central lymph node metastasis in group 2
All patients in group 2 underwent central cervical lymph node dissection as routine surgical treatment.
Thirty-two  patients  were  level VI  lymph node  positive  (26.0%)  while  91  were  negative.  The  FREQ
Procedure and Fisher Exact Test analysis showed that all variables assessed, including sex, age and tumor
size were not significantly predictive of central lymph node metastasis (p>0.05). However, multifocality of
the tumor was found to be one of the factors significantly increasing the risk of central cervical lymph
node metastasis (p=0.013)(Table 2). Multifocality was also found to be an independent risk factor for
central cervical lymph node metastasis by logistic regression analysis (Table 3).
In group 2, 52 patients received a unilateral selective neck dissection and 1 patient received a bilateral
selective neck dissection. Among the 54 cervical lymph node dissection,10 neck dissections were positive
(18.5%) while  44 were  negative.  Among these  10 positive  neck dissections,  8  were  concurrent  with
central cervical lymph node  positive,  whereas other  2  dissections had a  skip lateral nodal metastasis
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without metastasis to the central compartment.
Surgical treatment of PTMC in our service
We have a routine treatment for the thyroid disease. We only operated on patients with thyroid nodules
more than 10mm or whose fine-needle aspiration biopsy was positive. Patients diagnosed as PTMC before
the operation or during the operation received a near total or total thyroidectomy with central cervical
lymph node dissection. Patients with suspicious cervical lymph node by clinical palpation or by cervical
ultrasound  received  a  selective  lymph  node  dissection.  Patients  who  were  diagnosed  as  PTMC
postoperation  underwent  subtotal thyroidectomy or  lobectomy and  did  not  received  more  aggressive
operation. All patients received postoperative thyroid stimulating hormone suppression thyroxine therapy
for life. No one received radioiodine.
Discussion
The wide spread use of neck ultrasound has allowed the detection of non palpable thyroid nodules as
small as 1-3 mm. When these nodules are included, the incidence of thyroid nodules may be as high as
70% in the general population (13, 14). In addition, ultrasound allows the biopsy of thyroid nodules that
are difficult  or impossible  to palpate because of their size  and location. The use of ultrasound-guided
fine-needle aspiration biopsy has resulted in a marked increase in the diagnosis of patients with PTMC and
in the number of patients operated on for small carcinomas. In 100% of subjects with PTMC in our study,
frozen section was performed during thyroid operation. We found that the frozen section remains the most
common  determinant  of  surgical  intervention,  when  not  all  the  patients  had  to  undergo  fine-needle
aspiration biopsy preoperatively.
Many researches (15, 16) have previously reported that a subtotal thyroidectomy is an effective surgical
treatment for incidental PTMC. For nonincidental cases, aggressive treatment is essential for reducing the
risk of cancer recurrence or mortality following surgery. Kalliopi (17) suggested when PTMC is diagnosed
preoperatively, routine total or near-total thyroidectomy is the treatment of choice, therapy should not
differ from that of larger tumors. In cases where a thyroid  lobectomy for benign thyroid disease was
performed,  if  a  unifocal PTMC with favorable  histological subtype,  no extension beyond the  thyroid
capsule, no lymph node metastases, and normal contralateral lobe are found, completion thyroidectomy
may be avoided and the patient’s follow-up may be limited to periodical neck ultrasound while undergoing
replacement L-T4 therapy.
In our study, we found that subtotal thyroidectomy is an effective surgical treatment for incidental PTMC,
as no one recurred during the follow-up. Near total or total thyroidectomy with central cervical lymph
node dissection is an adequate procedures for non-incidental PTMC, as ten-year disease-free and overall
survival rates were 99.4% and 100%. Only one patient relapsed after first surgical treatment. Completion
thyroidectomy is recommended in our service  in case  of multifocal disease,  unfavorable  histology, or
lymph node metastases. In this study, patients were started on suppressive L-thyroxine (L-T4) therapy to
achieve  a  low TSH level during follow-up.  Because  total thyroidectomy was not  the  routine  surgical
procedure in our series, patients did not undergo radioactive iodine ablation to achieve negative 131-I
whole-body scan and undetectable Tg levels during follow-up. We found that our treatment was effective
and consistent with China’s national conditions in order to reduce the operative complications and to give
patients proper not excessive treatment.
In group 1, the mean age of patients is older than that in group 2 and they had a smaller tumor size. A
recent study (15) of 335 cases also showed that there was no statistically significant difference of the
mean age between 2 groups and patients in incidental group had a smaller tumor size, few frequency of
multifocal, better prognosis than that of non incidental group. As the prognosis of PTMC is related to the
tumor size,  Pelizzo (18) suggested that  PTMC < 5 mm in diameter,  without  evidence of lymph node
involvement, partial thyroidectomy may be a viable approach to treatment. In our study, the mean tumor
size of group 1 is 0.33 cm, so our treatment for incidental PTMC is adequate.
We  have  systematically  assessed  the  pattern  of  central  cervical  nodal  metastasis  in  123  patients.
Multifocal PTMC was noted in 7.3% (9/123) of the patients in the group 2, in which 6 were central lymph
node positive. A similar study (19) showed that of the 72 patients with PTMC, no clinicopathologic factor
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predicted nodal metastasis. Despite the absence of palpable neck nodes, PTMC is associated with a high
rate of central lymph node metastasis which was 26% (32/123) in our study. Since the central cervical
lymph node dissection used the same incision as the original surgery, we suggested total thyroidectomy
with  central  cervical  lymph  node  dissection  was  more  effective  than  the  thyroidectomy  alone  for
managing non incidental PTMC. It can improve the quality of life and survival by reducing cervical lymph
node metastasis.
Ito (20) suggested if surgical treatment is performed for low-risk PTMC, prophylactic modified radical
neck  dissection  is  not  necessary.  In  our  study,  53  patients  in  group  2  with  concurrent  neck
lymphadenopathy  underwent  cervical lymph node  dissection,  including level II–IV,  10  were  (18.5%)
positive. Although PTMC had high metastatic activity, prophylactic neck dissection had been discouraged
for  patients  who present  without  palpable  neck  nodes because  lymph node  metastasis  had  not  been
considered  prognostic  for  survival  (21).  So  we  thought  if  the  patients  without  concurrent  neck
lymphadenopathy, it was unnecessary to undergo cervical lymph node dissection. According to our series,
we considered that  central cervical lymph node could also be regarded as the sentinel lymph node of
PTMC.
Conclusion
Subtotal thyroidectomy is an effective surgical treatment for incidental PTMC. Patients with multifocal
tumors may have  more  aggressive  surgical treatment.  Near  total or  total thyroidectomy with  central
cervical lymph node dissection is adequate procedures for non-incidental PTMC who without lymph node
metastasis.
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